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The thyroid TRK-T3 oncogene, produced by a chromosomal translocation, is a chimeric, constitutively activated version of the
NTRK1/NGF receptor and it is able to transform NIH3T3 cells and differentiate PC12 cells. TRK-T3 oncoprotein triggers
multiple signal transduction pathways. Among others, TRK-T3 binds and phosphorylates the Shc and SNT1/FRS2 adaptor
proteins both involved in coupling the receptor tyrosine kinase to the mitogen-activated protein kinase pathway by recruiting
Grb2/SOS. We were interested in deﬁning the role of Shc in the oncogenesis by TRK-T3. The mutation of TRK-T3 tyrosine
291, docking site for both Shc and FRS2, abrogates the oncogene biological activity. To directly explore the role of Shc we
used the ShcY317F mutant, which carries the mutation of a tyrosine residue involved in Grb2 recruitment. We demonstrated
that the ShcY317F mutant exerts an inhibitory effect on TRK-T3 transforming activity. Such effect can be modulated by the
amount of ShcY317F protein and affects the viability of cells expressing TRK-T3 by means of a mechanism involving apoptosis.
Our results indicate a deﬁnitive role of the adaptor protein Shc in TRK-T3 transforming activity.
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The thyroid TRK oncogenes are created by chromosomal rearran-
gements fusing the tyrosine kinase (TK) domain of the NTRK1/
NGF receptor to the 5'-end portion of different activating genes
(Pierotti et al, 1996). In the TRK-T3 oncogene, produced by a
t(1;3) translocation, the NTRK1 TK domain is juxtaposed to
sequences of the TFG gene (Greco et al, 1995), which encodes a
protein of unknown function containing a coiled-coil domain,
putative phosphorylation sites for PKC and CK2 and glycosylation
sites (Mencinger et al, 1997; Mencinger and Aman, 1999). The TFG
coiled-coil domain plays an important role in TRK-T3 activation
and its consequent biological activity insofar as it mediates the
dimerization leading to the ligand-independent tyrosine phosphor-
ylation of the TK domain. Moreover, also the regions outside the
coiled-coil domain are required for TRK-T3 transforming activity
(Greco et al, 1998) in ways that are currently under investigation.
Signalling by the NTRK1 receptor has been extensively studied
and it involves both Ras-dependent and Ras-independent path-
ways. Ligand activation leads to the phosphorylation of ﬁve
tyrosine residues in the intracellular domain of NTRK1: Tyr490
in the juxtamembrane region, Tyr670, Tyr674, Tyr675 within the
TK domain, and Tyr785 in the carboxyl-terminal tail. Phosphory-
lated Tyr490 provides the docking site for and mediate the
phosphorylation and activation of Shc and SNT1/FRS2, two adap-
tor proteins signalling through the Ras/MAPK cascade;
phosphorylated Y785 recruits and activates PLCg (Kaplan and
Miller, 1997; Meakin et al, 1999). The other three tyrosines are
required for kinase activity, and recent studies have shown that
they are also involved in the activation of rAPS and SH2-B (Qian
et al, 1998) and the direct recruitment of Grb2 (MacDonald et al,
2000). The common downstream effectors of Shc, FRS2, Grb2,
rAPS and SH-2B are ERK1/2 MAP kinases, followed by the activa-
tion of transcription factors and the induction of immediate early
genes.
Shc adaptor proteins are cytoplasmic substrates for a number of
receptor and non-receptor tyrosine kinases (TKs), including NTRK1
(van der Geer et al, 1995). By both alternative splicing and tran-
scription start sites three protein isoforms of 66, 52 and 46 kDa
are produced. The Shc p52/46 isoforms are involved in the trans-
mission of signals from activated TKs (Migliaccio et al, 1997),
and the Shc p66 isoform controls stress apoptotic responses and life
span (Migliaccio et al, 1999). In addition to collagen homology
(CH) domains, Shc proteins have phosphotyrosine binding (PTB)
and Src homology 2 (SH2) domains (Migliaccio et al, 1997; Pelicci
et al, 1992) both involved in exclusive or cooperative binding to
phosphotyrosine residues. Upon receptor binding, Shc undergoes
phosphorylation at three tyrosine residues (317, 239 and 240),
becomes capable of interacting with the SH2 domain of Grb2,
and causes the activation of the SOS/Ras/MAPK pathway. Different
roles have been ascribed to Tyr317 and Tyr239/240, depending on
the cell environment and on the kinase that trigger Shc activation.
In hematopoietic cells and in EGF-stimulated NIH3T3 phosphory-
lation of Tyr317 has been proposed to trigger MAPK activation. On
the contrary, phosphorylated Tyr239/240 signal to c-myc and thus
regulate IL-3 dependent apoptosis in haematopoietic cells and
contribute to the EGF-induced proliferation of NIH3T3 ﬁbroblasts
(Gotoh et al, 1996, 1997). In RAT-2 cells transformed by VEGF
receptor, Tyr239/240 mediate an inhibitory signal for cell growth
(Fournier et al, 1999). In PC12 cells Tyr239/240, but not Tyr317,
play an important contribution to the NGF-induced Ras/MAP
kinase activation and differentiation (Thomas and Bradshaw,
1997). It is therefore possible that the signalling pathway of
Tyr239/240 may involve effectors other than Grb2.
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Received 19 February 2002; revised 25 June 2002; accepted 26 June 2002
*Correspondence: A Greco; E-mail: greco@istitutotumori.mi.it
British Journal of Cancer (2002) 87, 645–653
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comThe involvement of Shc in NTRK1 signal transduction has been
demonstrated by various studies (Obermeier et al, 1993; Stephens
et al, 1994). In a previous work we detected interaction of Shc
SH2 domain with the wild type NTRK1 receptor and various
TRK oncogenes expressed in NIH3T3 cells (Borrello et al, 1994).
After the subsequent discovery of the Shc PTB domain, experi-
ments with PC12 cells showed that Shc PTB domain interacts
with Tyr490 of the activated NTRK1 receptor, whereas the interac-
tion with an unidentiﬁed p115 phosphoprotein was proposed for
the SH2 domain (Dikic et al, 1995).
As we are interested in elucidating the signal transduction path-
ways leading to the TRK oncogene transformation of NIH3T3 cells,
we began by investigating the involvement of the proteins known
to transduce NTRK1 signals. This apparently obvious approach is
not as trivial as it may seem because NGF-induced NTRK1 activa-
tion leads to cell type speciﬁc biological effects, such as the
differentiation of neuronal cells, the apoptosis of medulloblastoma
cells and the mitogenesis of non-neuronal cells (Muragaki et al,
1997). This suggests that the critical elements of NTRK1 signalling
may vary in cell lines from different tissues. In addition to differ-
ences due to cell speciﬁcity, TRK oncogenes may trigger signal
transduction pathways other than the wild type receptor as a
consequence of the properties contributed by structural rearrange-
ments (cytoplasmic localization, the presence of activating
sequences).
In a previous study we demonstrated that Shc is activated by
TRK oncoproteins and therefore capable to recruit Grb2 (Borrello
et al, 1994). We have more recently also determined the activation
of FRS2, PLCg, ERK1/2 and JNK MAP kinases in cells transformed
by TRK-T3 (Greco et al, manuscript in preparation), as well as the
recruitment of IRS1 and IRS2 by NTRK1 and TRK-T1 oncogene
(Miranda et al, 2001).
In the study reported here we investigated the contribution of
the Shc adaptor in TRK-T3 signal transduction. The mutation of
the docking site for both Shc and FRS2 abolished the TRK-T3
biological activity, thus indicating that possible other pathways
might not overcome the lack of the two adaptors. To further deﬁne
the role of Shc in TRK-T3 activity we used the ShcY317F domi-
nant-negative mutant, in which one of the tyrosines recruiting
the Grb2/SOS complex has been mutated to phenylalanine. Our
data show that ShcY317F reduces TRK-T3 biological activity, thus
indicating the indispensability of Shc. Moreover, we report
evidences that cells expressing both TRK-T3 and ShcY317F under-
go cell death by a mechanism involving apoptosis.
MATERIALS AND METHODS
Plasmid construction
The T3/WT plasmid contains the TRK-T3 cDNA inserted into
the pRC/CMV expression vector (Greco et al, 1995), which
carries the neomycin resistance gene. The T3/Y291F mutant
carries the mutation of Tyr291 to phenylalanine (F291) and
was constructed by means of site-directed mutagenesis using an
in vitro oligonucleotide mutagenesis system (Altered Sites in vitro
Mutagenesis System, Promega). The T3/ABN kinase-defective
mutant carries the mutation of the ATP binding site Lys339 to
Ala (Greco et al, 1998). In ShcY317F mutant the Tyr317 is
mutated to Phe. The cDNAs encoding ShcWT and ShcY317F
are inserted in the pCGN expression vector, containing the
hygromycin-resistance gene, and are tagged by the HA epitope
at the N-terminus.
The VGF8-luc is a reporter plasmid made of vgf promoter
sequence fused to the luciferase reporter gene (a kind gift from
Dr R Possenti).
The pRL-CMV vector, containing the coding region of the
Renilla luciferase (RL) gene, was provided by Promega.
Cell culture and transfection
Mouse NIH3T3 ﬁbroblasts were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% calf serum,
human kidney 293T cells in DMEM supplemented with 10% foetal
calf serum, and transformed cell lines in DMEM supplemented
with 5% calf serum. PC12 cells were grown in RPMI-1640 medium
supplementd with 5% foetal calf serum and 10% horse serum.
NF797 cells are NIH3T3 cells transformed by the TRK-T3 onco-
gene; NWT and NY317F cell lines are derived from NIH3T3 cells
respectively transfected with ShcWT and ShcY317F plasmids, and
selected in the presence of hygromycin (25 mgm l
71). 3.9HG are
semi-transformed cells generated by the transfection of NY317F
cells with the TRK-T3 oncogene and isolated in medium supple-
mented with 5% calf serum plus hygromycin (25 mgm l
71) and
G418 (400 mgm l
71).
The NIH3T3, NWT and NY317F cells (8610
4/60 mm plate)
were transfected by the CaPO4 method as previously described
(Bongarzone et al, 1989), using 250 ng of expression plasmid
DNA together with 15 mg of mouse DNA. Transformed foci were
selected in DMEM supplemented with 5% serum, in the presence
or absence of hygromycin (25 mgm l
71), G418 (400 mgm l
71)o r
both. G418- and hygromycin-resistant colonies were selected in
DMEM plus 10% serum containing the selective agents at the
above concentrations. The transformed foci and resistant colonies
were either ﬁxed or isolated for further studies 2 weeks after trans-
fection. The 293T cells were transiently cotransfected with T3/WT
or T3/mutants (1 mg) together with Shc constructs or pCGN empty
vector (5 mg) using the CaPO4 method. The cells were kept in 10%
serum medium for 6–7 h, serum-starved overnight in DMEM
containing 0.5% FCS, and then processed for protein extraction.
PC12 cells were transfected using Cellfectin (Lifetechnologies,
Inc.). Cells (2610
5) were seeded on collagen-coated 12-multiwell
plates and transfected with 400 ng of T3/WT or T3/Y291F plasmid.
In cotransfection experiments 100 ng of T3/WT together with
500 ng of ShcWT, ShcY317F or pCGN plasmid were used. Speciﬁc
plasmid DNA were transfected together with 150 ng of VGF8-luc
plasmid and 50 ng of pRL-CMV plasmid (Promega). Cells were
incubated with the reagent for 7 h and scored for neurites
outgrowth 2 days later.
Luciferase activity assay
Both luciferase activities of VGF8-luc and pRL-CMV genes in PC12
cells lysates were measured using the Dual-luciferase reporter assay
system (Promega). Assays were performed according to the manu-
facturer’s recommendations. Light emission was measured using a
TD-20/20 Luminometer.
Microfocus forming assay
The assay was performed as described by Li et al (1999). One
hundred cells from NF797 cell lines transfected with pCGN vector,
ShcWT or ShcY317F were combined with 1610
5 NIH3T3 cells in
10-cm dishes, and cultured for 2 weeks in medium containing 5%
calf serum. The foci were counted after GIEMSA staining.
Immunoprecipitation, pull-down and Western blot
analysis
Cells were lysed with PLCLB buffer (50 mM HEPES, 150 mM NaCl,
10% glycerol, 1% Triton X-100, 1.5 mM MgCl2,1 m M EGTA,
10 mM Na4P2O7, 100 mM NaF) supplemented with aprotinin,
pepstatin, leupeptin, PMSF and Na3VO4. One milligram of the cell
extracts was precipitated with the appropriated antibodies, or with
GST-Grb2(SH2) fusion protein conjugated to gluthatione-sephar-
ose, or with p13suc1-agarose. The precipitates were washed three
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Triton X-100, 10% glycerol) and boiled in Laemmli sample buffer.
Protein samples were electrophoresed on 8.5% SDS–PAGE, trans-
ferred onto nitrocellulose ﬁlters and immunoblotted with the
appropriated antibodies. The immunoreactive bands were visua-
lised using horseradish peroxidase-conjugated secondary antibody
and enhanced chemiluminescence (Amersham). The anti-TRK
and anti-Grb2 antibodies were from Santa Cruz Biothec., Inc.;
the anti-HA antibodies were from BabCo; the anti-Shc, anti-
FRS2, anti-phosphotyrosine antibodies and the p13suc1-agarose
were from Upstate biothecnology, Inc.
TUNEL analysis of DNA fragmentation
In situ detection of apoptotic cells was performed on adherent cells
cultured on chamber slides by using the In Situ Cell Death Detec-
tion Kit, Fluorescein (Boehringer Mannheim), according to the
manufacturer’s instruction. The slides were then counterstained
with 4',6-diamin2-phenylindole.
RESULTS
TRK-T3 biological activity requires the Shc/FRS2 docking
site
The Tyr490 residue of the NTRK1 receptor is involved in the
recruitment and activation of Shc adaptor proteins; such interac-
tion occurs through the Shc PTB domain (Dikic et al, 1995).
Tyr490 is also the docking site for SNT1/FRS2, a myristilated adap-
tor molecule signalling through Grb2/SOS/ERKs (Rabin et al, 1993;
Kouhara et al, 1997; Ong et al, 2000). In vitro studies have shown a
competition between Shc and FRS2 for the binding to the phos-
phorylated Tyr490 of NTRK1 (Meakin et al, 1999). With the
ﬁnal aim to provide evidences of possible oncogene-speciﬁc signal
transduction pathways that could bypass the need for Shc and
FRS2, we deﬁned the role of TRK-T3 Tyr291 (corresponding to
NTRK1 Tyr490) in the oncogene biological activity. The tyrosine
residue was changed to phenylalanine by site-directed mutagenesis,
to produce T3/Y291F (Figure 1). Wild type and Y291F TRK-T3
cDNAs were inserted into the pRC/CMV mammalian expression
vector, which also carries the neomycin resistance gene. Transient
expression into human kidney 293T cells showed that, similarly
to the wild type, the T3/Y291F mutant produced a phosphorylated
68 kDa protein (Figure 2A). Western blot analysis of Shc immuno-
complexes hybridised with anti-TRK (Figure 2A) showed that the
T3/Y291F mutant is unable to interact with Shc (Figure 2A). The
same cell extracts were incubated with the FRS2 interacting protein
p13suc1 conjugated to agarose beads. The complexes immunoblot-
ting with anti-FRS2 antibodies showed a constitutive association of
FRS2 with p13suc1. However, immunoblotting with anti-phospho-
tyrosine antibodies showed that FRS2 is activated by TRK-T3 wild
type but not by the T3/Y291F mutant.
We next analysed the transforming activity of T3/Y291F mutant
by NIH3T3 transfection/focus formation experiments. As reported
in Figure 2B, the transfection efﬁciency of T3/Y291F, determined as
frequency of G418-resistant colonies, was slightly higher than wild
type. However, the capacity to induce NIH3T3 transformation was
completely abolished in the mutant oncogene. The biological effect
of T3/Y291F mutant was also investigated in PC12 cells, in which
the constitutively activated TRK oncogenes recapitulate the neuro-
nal differentiating effect of NGF-stimulated NTRK1 receptor. As
shown in Figure 2C T3/Y291F failed to induce neurites outgrowth.
To quantify the differentiating activity of the TRK-T3 constructs
we performed PC12 transfection in the presence of the VGF8-luc
reporter plasmid; the latter is made of the luciferase reporter gene
driven by the promoter of the vgf, a gene induced by NGF and
considered a differentiation marker (Possenti et al, 1992; Canu et
al, 1997). As shown by the graph in Figure 2C, the luciferase activ-
ity in cells expressing T3/Y291F is drastically reduced (86%) with
respect to T3/WT.
All these results demonstrated that the Y291F mutation abro-
gates the TRK-T3 interaction with Shc and FRS2 adaptors and,
consequently, its biological activity. This demonstrates that possible
novel signal transduction pathways triggered by the rearranged
versions of the NTRK1 receptor may not compensate the need of
Shc and FRS2 signalling.
Effect of ShcY317F mutant on TRK-T3-dependent signal
transduction
As a tool for deﬁning the role of Shc adaptor in TRK-T3 signal
transduction we used the ShcY317F mutant of the 52 kDa Shc
isoform (Figure 1), in which the tyrosine 317 has been changed
to phenylalanine. Tyr317 of Shc, in addition to Tyr239/240,
recruits Grb2 upon phosphorylation; the ShcY317F mutant has
been shown to exert a dominant-negative effect in different biolo-
gical processes mediated by Shc (Li et al, 1999; Stevenson et al,
1999; Boney et al, 2000; Mercalli et al, 2001). The ShcY317F and
the control ShcWT constructs (Figure 1) were tagged by the
haemoagglutinin (HA) epitope, which confers a small electrophore-
tic shift with respect to the endogenous p52 Shc, and cloned into
the pCGN expression vector harbouring the resistance to hygromy-
cin.
We investigated the capability of ShcY317F to interact with
TRK-T3 oncoprotein. Human kidney 293T cells were transiently
cotransfected with TRK-T3 or T3/ABN kinase-dead mutant,
together with HA-tagged ShcWT, ShcY317F or the pCGN vector
as control (Figure 3). The expression of the transfected proteins
is shown in Figure 3C. Similarly to ShcWT, the 53 kDa phosphory-
lated ShcY317F protein coprecipitated with TRK-T3, as shown by
the anti-phosphotyrosine Western blot hybridisation of anti-TRK
immunocomplexes. This interaction required the phosphorylation
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TFG NTRK-1
CC TM TK
Y291 Y470
Y475
Y476
Y586
T3/WT
CC TM TK
F291 Y470
Y475
Y476
Y586
HA PTB CH1 SH2
HA PTB CH1 SH2
Y239/240 Y317
Y239/240 F317
T3/Y291F
ShcWT
ShcY317F
Figure 1 Schematic representation of TRK-T3 and Shc constructs. In the
TRK-T3 constructs the portions contributed by TFG and NTRK1 are
shown, with an arrowhead indicating the breakpoint. The coiled-coil
(CC), transmembrane (TM) and tyrosine kinase (TK) domains are indi-
cated. The tyrosine residues involved in Shc and FRS2 interaction (Y291),
PLCg interaction (Y586) and tyrosines of the activation loop (Y470,
Y475 and Y476) are indicated. In T3/Y291F mutant the tyrosine 291 has
been mutated to phenylalanine (F291). The TRK-T3 cDNAs were inserted
into the pRC/CMV expression vector. The Shc constructs show the PTB
domain, the collagen homology region (CH1) and the SH2 domain.
Y239/240 and Y317 are tyrosine residues phosphorylated by tyrosine
kinases. In ShcY317F, tyrosine 317 is mutated to phenylalanine (F317).
The Shc cDNAs contain the HA epitope at the N-terminus and were in-
serted into the pCGN mammalian expression vector.
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mutant (Greco et al, 1998) was used (Figure 3A).
We next investigated the ability of ShcY317F to recruit Grb2
upon TRK-T3 activation. The same cell extracts as above were
incubated with the GST-Grb2(SH2) fusion protein, containing
the Grb2 SH2 domain. Hybridisation with anti-HA antibodies
(Figure 3B, top) showed that the amount of ShcY317F protein
reacting with GST-Grb2(SH2) is lower than ShcWT, in accor-
dance with the lack of an interaction site. The ShcY317F-Grb2
interaction was also investigated by coimmunoprecipitation
experiments. The above cell extracts were immunoprecipitated
with anti-Grb2 antibodies and hybridised with antiphosphotyro-
sine antibodies. Similarly to ShcWT and endogenous Shc
proteins (data not shown), phosphorylated ShcY317F coprecipi-
tated with Grb2 (Figure 3B, bottom). The ShcY317F-Grb2
interaction depends on the TRK-T3-triggered Shc activation, being
undetectable when the T3/ABN kinase-dead mutant was used.
Grb2 immunocomplexes also contain the phosphorylated TRK-
T3 oncoprotein (Figure 3B, bottom), as consequence of both
direct (MacDonald et al, 2000) and Shc/FRS2-mediated interac-
tion. Altogether these results indicate that ShcY317F is
phosphorylated by TRK-T3 at tyrosine residues 239/240 and
therefore capable of recruiting Grb2.
As reported in the previous paragraph, both Shc and FRS2 bind,
in a competitive manner, to phosphorylated NTRK1 Tyr490 resi-
due (Meakin et al, 1999). We investigated the effect of ShcY317F
on FRS2 activation induced by TRK-T3. The same cell extracts
from serum-starved 293T cells transiently cotransfected with
TRK-T3 and ShcWT, ShcY317F or the pCGN vector as control
were pulled-down with the FRS2-interacting p13suc1 protein
conjugated to agarose beads, and the eluted complexes analysed
by Western blot. As shown in Figure 3D, hybridisation with
anti-phosphotyrosine antibodies detected comparable levels of
FRS2 phosphorylation in cells expressing TRK-T3 in combination
with the pCGN empty vector, ShcWT or the ShcY317F mutant.
As control, the expression of FRS2 is shown. These results indicate
that, in our experimental conditions, although in the presence of
exogenous Shc proteins, Tyr291 of TRK-T3 is still capable to signal
through FRS2.
Inhibitory effect of ShcY317F mutant on TRK-T3 biological
activity
In the ﬁrst paragraph we have shown that the biological activity of
TRK-T3 is abrogated by the mutation of the Tyr291, docking site for
Shc and FRS2. To directly explore the role of the Shc adaptor in
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Figure 2 Biochemical and biological analysis of T3/Y291F mutant. (A) T3/WT or T3/Y291F expression plasmids were transiently transfected into 293T
cells. Cell extracts were immunoprecipitated (IP) with the antibodies anti-TRK, anti-Shc or with p13suc1-agarose and blotted with anti-phosphotyrosine,
anti-TRK, anti-Shc and anti-FRS2 antibodies. (B) Effect of the Y291F mutation on TRK-T3 transforming activity. NIH3T3 cells were transfected with the in-
dicated constructs and subjected to G418 and foci selection. Plates were ﬁxed and scored after GIEMSA staining 2 weeks later. (C) Effect of the Y291F muta-
tion on TRK-T3 differentiating activity. PC12 cells were transfected with the indicated constructs and scored for the presence of neurites 3 days later. As
control, untreated and NGF-stimulated (50 ng ml
71) PC12 cells are shown. The graph shows a quantiﬁcation of differentiating activity. TRK-T3 constructs
were cotransfected with VGF8-luc and Renilla plasmids; both luciferase activities were measured using the Dual-Luciferase reported assay system (Promega).
The values were expressed relative to Renilla luciferase activity for normalization. The results presented are an average of three experiments.
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ShcY317F dominant-negative mutant on TRK-T3 biological activity.
We ﬁrst investigated the effect of ShcY317F on TRK-T3 differen-
tiating activity. PC12 cells were cotransfected with TRK-T3
together with HA-tagged ShcWT, ShcY317F or the pCGN empty
vector. The results are reported in Figure 4A. Three days after
transfection cell transfected with TRK-T3 and ShcWT or pCGN
displayed long neurites. On the contrary, cells transfected with
TRK-T3 and ShcY317F showed shorter extentions, with a few of
them exceeding the cell diameter. As control the expression of
TRK-T3 and HA-tagged Shc proteins is reported (Figure 4A).
The differentiating activity was measured by cotransfecting the
VGF8-luc reported plasmid, as above described. Luciferase activity
in cells expressing T3/WT and ShcY317F was reduced to 50% with
respect to cells expressing T3/WT and ShcWT (graph in Figure
4A).
We next investigated the effect of ShcY317F mutant on TRK-T3
transforming activity. As ﬁrst approach we performed the microfo-
cus formation assay. NF797 cells (NIH3T3 transformed by the
TRK-T3 oncogene) were transfected with ShcY317F and ShcWT
or the empty pCGN vector as control, as described in Materials
and Methods. Transfected cells were mixed with an excess of wild
type NIH3T3 cells, seeded in medium containing 5% calf serum,
and their ability to form foci was assessed. As shown in Figure
4B focus forming capability was unaffected in the NF797 cells
transfected with pCGN and ShcWT, but was reduced by about
50% in the cells expressing ShcY317F.
To more directly explore the effect of ShcY317F on TRK-T3
induced transformation we constructed NIH3T3 cell lines expres-
sing exogenous ShcWT and ShcY317F proteins. The Shc
constructs (Figure 1), as well as the pCGN empty vector, produced
hygromycin-resistant NIH3T3 colonies with equivalent efﬁciency
(data not shown), thus demonstrating that the overexpression of
wild type and Y317F Shc proteins does not interfere with the
growth of normal NIH3T3 cells. Several colonies were isolated
and analysed for the expression of the transfected Shc constructs
(data not shown). Selected cell lines (clone NWT for ShcWT and
clone NY317F for ShcY317F) were used as recipients for focus
formation assay. Both cell lines were transformed by Ha-ras and
TRK-T3 oncogenes with comparable efﬁciency (data not shown).
However, whereas the Ha-ras foci displayed similar size in both
recipient cell lines (data not shown), the foci induced by TRK-
T3 in NY317F cells were smaller than those in NIH3T3 and
NWT (Figure 4C). This difference is related to the inhibitory effect
of ShcY317F rather than the growth rate of the NY317F parental
cell line, as deduced by growth curve determination (unpublished
observations).
In order to characterise further the inhibitory effect of ShcY317F
on TRK-T3 transforming activity, we investigated the inﬂuence of
the level of Shc mutant protein expression. To this aim we
performed foci selection in the presence of hygromycin, whose
resistance is carried by the pCGN expression vector, based on
previous observations showing that the level of ShcWT and
ShcY317F proteins increases when NWT and NY317F cells are
cultured in the presence of the antibiotic (unpublished results).
As shown in Figure 4D, the addition of hygromycin did not affect
the transforming activity of TRK-T3 in NWT cells. On the
contrary, hygromycin reduced the number of foci induced by
TRK-T3 in NY317F cells by about 60%, both in the presence
and in the absence of G418, whose resistance is carried by the
TRK-T3 expression vector. The presence of hygromycin also
reduced the size of foci in NY317F cells (data not shown). These
results support the view that ShcY317F exerts an inhibitory effect
on TRK-T3 transforming activity, which can be modulated by
the protein amount.
Long-term effects of ShcY317F on the TRK-T3 induced
transformed phenotype
Having shown that ShcY317F reduced TRK-T3 transforming activ-
ity, we were interested in determining any long-term effect in foci
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Figure 3 (A) ShcY317F is phosphorylated by TRK-T3. 293T cells were
transiently cotransfected with the indicated constructs. Cell extracts were
immunoprecipitated (IP) with anti-TRK and immunoblotted (WB) with
anti-phosphotyrosine antibodies. The TRK-T3 oncoprotein, the 53 kDa
HA-tagged ShcWT and ShcY317F transfected proteins are indicated. Cells
cotransfected with T3/WT and pCGN vector were used as negative con-
trol. (B) Interaction of transfected Shc proteins with Grb2. The above de-
scribed cell extracts were incubated with the GST-Grb2(SH2) fusion
protein (top) or immunoprecipitated with anti-Grb2 antibodies (bottom)
and hybridised with anti-HA and anti-phosphotyrosine antibodies, respec-
tively. The phosphorylated proteins present in the anti-Grb2 immunocom-
plexes are indicated. (C) To show the expression of the transfected
proteins, cell extracts above described were immunoblotted with anti-
HA and anti-TRK antibodies. (D) Effect of ShcY317F mutant on TRK-T3
induced FRS2 activation. The same cell extracts above described, except
T3/ABN-ShcY317F cotransfection, were pulled down with p13suc1-agar-
ose and immunoblotted with anti-phosphotyrosine or anti-FRS2 antibodies.
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Figure 4 (A) Effect of ShcY317F on TRK-T3 induced PC12 differentiation. PC12 cells were cotransfected with TRK-T3 and ShcWT (a), ShcY317F (b) or
pCGN (c) plasmids, together with VGF8-luc and Renilla plasmids, as described in Materials and Methods and scored for the presence of neurites 3 days later.
As control, untreated (d) and NGF-stimulated (50 ng ml
71) (e) PC12 cells are shown. After morphological analysis, transfected PC12 cells were lysates and
subjected to immunoblot using anti-TRK and anti-HA antibodies to detect the level of transfected proteins. To quantify the TRK-T3 differentiating activity
both luciferase activities were measured using the Dual-Luciferase reported assay system (Promega). The values were expressed relative to Renilla luciferase
activity for normalisation. The results presented are an average of three experiments. (B) Microfocus formation assay. One hundred cells from focus NF797
(NIH3T3 cells transformed by TRK-T3 oncogene) transfected with pCGN vector, ShcWT or ShcY317F constructs were combined with 1610
5 NIH3T3
cells in 10-cm dishes, and cultured for 2 weeks in medium containing 5% calf serum. The foci were counted after GIEMSA staining. (C) Transforming activity
of TRK-T3 in NIH3T3, NWT (NIH3T3 cells stably expressing ShcWT) and NY317F (NIH3T3 cells stably expressing ShcY317F) cells. Transfection and foci
selection were performed as described in Materials and Methods. Foci and G418 resistant colonies were either ﬁxed and GIEMSA stained or isolated for
further analysis after two weeks of selection. (D) Effect of hygromycin on TRK-T3 foci formation in NWT and NY317F cell lines. Foci selection was per-
formed in 5% serum medium supplemented or not with 400 mgm l
71 of G418 (selectable marker contained in the TRK-T3 expression vector) in the ab-
sence or presence of 25 mgm l
71 hygromycin (selectable marker contained in the Shc expression vector). Foci were scored after 2 weeks of selection. For
each cell line, the number of foci per mg DNA selected in the absence of hygromycin was set at 100%.
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ShcY317F mutant. Several foci were isolated, in the presence or
absence of hygromycin and/or G418 (as above reported, Figure
4D) with the aim of enhancing the expression of ShcY317F and/
or TRK-T3 proteins. Interestingly, a difference was evident after
isolation: the morphology of the TRK-T3 foci in NY317F cells
was less transformed than that of the foci in NIH3T3 and NWT
cells, and will be subsequently called ‘intermediate’ (Table 1). Soon
after isolation (‘early’ in Table 1), Western blot analysis and/or
immunoﬂuorescence revealed that all the foci in NY317F cells
expressed both TRK-T3 and ShcY317F proteins (data not shown).
Later on the behaviour of the foci during culture varied according
to the method of selection. The foci selected in the presence of
hygromycin, which increased the level of ShcY317F protein, under-
went a growth crisis starting 4 weeks after isolation. Most of the
cells died; the surviving cells had a ﬂat phenotype, and they could
be rescued and propagated by increasing the serum concentration
up to 10% (‘late’ in Table 1). At this stage Western blot and/or
immunoﬂuorescence analysis of the rescued cells showed loss of
TRK-T3 expression, but no changes in ShcY317F expression. The
same effect was observed in half of the foci isolated in the absence
of selective agents, whereas the remaining 50% maintained the
intermediate phenotype and the expression of TRK-T3 protein,
but lost the expression of ShcY317F. The foci selected in the
presence of both hygromycin and G418 maintained the intermedi-
ate phenotype and the expression of both TRK-T3 and ShcY317F
proteins. Altogether these results indicate that TRK-T3 full trans-
forming activity requires signaling through tyrosine 317 of Shc.
To get inside the cell death described above, the TRK-T3
induced NY317F foci were monitored twice a week for the occur-
rence of apoptosis by TUNEL. Although there was considerable
variability among the clones, 2–10% of TUNEL-positive cells
was detected in those undergoing a growth crisis and loosing
TRK-T3 expression. By contrast, when the parental NY317F cell
line or a NIH3T3 focus transformed by TRK-T3 were analysed,
no TUNEL-positive cells were scored. Furthermore, the number
of TUNEL-positive cells may have been underestimated because
TUNEL picks up the late stage of apoptosis marked by DNA
breaks. These results suggest that the inhibitory effect of ShcY317F
on TRK-T3 transforming activity involves apoptosis.
The effect of selective agents on the transformed phenotype and
ShcY317F and TRK-T3 protein expression was recapitulated on
focus 3.9HG, which was selected and expanded in the presence of
both hygromycin and G418, and had an ‘intermediate’ phenotype.
The cells were cultured in the presence and absence of hygromycin
and/or G418 (Figure 5). After one month, the cells kept in the
absence of selective agents or in the presence of G418 alone were
more transformed than those kept in the presence of both agents,
whereas those exposed to hygromycin alone were completely ﬂat
(Figure 5A). Western blot analysis demonstrated that the level of
TRK-T3 protein was enhanced by G418 and that of ShcY317F
protein was enhanced by hygromycin. Furthermore, the expressions
of TRK-T3 and ShcY317F were inversely correlated, and the trans-
formed and ﬂat phenotypes respectively correlated with high
expression of TRK-T3 and ShcY317F (Figure 5B). These results
conﬁrm the considerations deduced from the focus formation assay
in NY317F cells, and indicate that TRK-T3 induced transformation
is maintained only if endogenous Shc signalling is preserved.
DISCUSSION
TRK oncogenes, associated with a consistent fraction of human papil-
lary thyroid carcinoma, are generated by somatic rearrangements and
display constitutive tyrosine kinase activity (Pierotti et al, 1996). The
biological effects of rearranged TRK oncogenes recapitulate that of
NGF-stimulated wild type NTRK1 receptor. In fact, similarly to the
activated receptor counterpart, TRK oncogenes induce transforma-
tion of NIH3T3 mouse ﬁbroblasts and differentiation of rat
pheochromocytoma PC12 cells. Analysis of TRK oncogenes signal
transduction, performed in NIH3T3 foci, have detected the involve-
ment of several signal transducers recruited by the NGF-stimulated
NTRK1 receptor, such as Shc, PLCg, ERK1/2 and JNK MAP kinases
(Borrello et al, 1994, manuscript in preparation).
With the aim to understand the mechanism leading to thyroid
transformation, we explored the role of the Shc adaptor protein
in the signal transduction triggered by TRK-T3 oncogene. The
mutation of TRK-T3 tyrosine 291, corresponding to the tyrosine
490 of the NTRK1 receptor, abolished the interaction with both
Shc and FRS2 adaptor proteins. This led to the abrogation of
TRK-T3 induced differentiation and transformation, thus demon-
strating that signalling through tyrosine 291 is essential for
oncogene activity and it cannot be compensated by possible TRK
oncogene-speciﬁc signal transduction pathways.
To assess more directly the role of Shc in TRK-T3 activity, we
used the ShcY317F mutant, carrying the mutation of the tyrosine
317 which, in addition to tyrosines 239/240, is involved in Grb2
recruitment. The ShcY317F mutant has been shown to exert a
dominant-negative effect on the endogenous Shc activity in differ-
ent contexts. In ErbB2-positive breast cancer cell lines, ShcY317F
blocks growth by disrupting cell-cycle progression (Stevenson et
al, 1999); in NIH3T3 cells it reduces the RET/PTC2 oncogene
transforming activity (Mercalli et al, 2001); in adipocytes it
suppresses the IGF-induced proliferation (Boney et al, 2000);
moreover, a Shc mutant lacking the CH1 domain that includes
Y317, suppresses NIH3T3 transformation induced by the neu
oncogene (Li et al, 1999).
The evidence that the ShcY317F mutant is tyrosyl phosphory-
lated when coexpressed with TRK-T3 indicates that the oncogene
targets residues Tyr239/240 of Shc. However, the capabilty of phos-
phorylated ShcY317F to interact with Grb2 is reduced with respect
to ShcWT. The expression of ShcY317F protein did not affect the
capability of TRK-T3 to recruit and activate FRS2. Nevertheless,
ShcY317F had an inhibitory effect on TRK-T3 induced differentia-
tion and transformation, thus supporting the hypothesis that Shc
signalling through Y317 is indispensable for TRK-T3 activity.
Our data on NIH3T3 transformation showed that such inhibitory
effect depends on the relative amount of TRK-T3 and ShcY317F
proteins. Indeed, inhibition is more evident by adding hygromycin
to the selection medium: this increases the amount of ShcY317F
protein, thus producing the greatest competition with endogenous
Shc for binding to TRK-T3. ShcY317F produced effect not only on
the foci number, but also on their morphology, which was manifest
upon isolation: foci arose in the presence of ShcY317F were less
transformed, and were named ‘intermediate’. In addition to these
short-term effects on transforming activity, a long-term effect
was observed in the cell lines expressing both TRK-T3 and
ShcY317F proteins selected as foci of ‘intermediate’ phenotype.
In most cases the clones underwent cell death, and the surviving
population lost the transformed morphology and TRK-T3 onco-
gene expression. Other clones maintained the transformed
morphology and oncogene expression either because the ShcY317F
protein was not sufﬁcient to titer out the wild type or because they
compensated the inhibitory effect of ShcY317F by accessory
mechanisms. The inhibition of TRK-T3 activity by ShcY317F is
therefore related to effect on both proliferation and transformation.
In clones undergoing cell death we observed a signiﬁcant
number of apoptotic cells. This ﬁnding is in keeping with recent
data suggesting that Shc plays a role in promoting cell survival
and counteracting apoptosis in response to cytokine receptors
(Gu et al, 2000) and NGF receptor (Ulrich et al, 1998; Ashcroft
et al, 1999) stimulation. The occurrence of apoptosis in our experi-
mental system can be explained by several hypotheses: (1) Shc
might transduce possible TRK-T3 anti-apoptotic signals; (2) signal-
ling through tyrosine 317 of Shc could counteract a possible pro-
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might be the consequence of cell stress due to incorrectly trans-
duced TRK-T3 signalling. Interestingly, results similar to ours
have been obtained by co-expressing ShcY317F and the Ret/PTC2
oncogene (Mercalli et al, 2001), thus indicating the existence of a
mechanism shared by other RTK oncogenes.
In conclusion, our data demonstrate that signalling through
ShcY317 is essential for TRK-T3 transformation. This residue
may cooperate with Tyr239/240 and/or other pathways in such a
way that, when mutated, the signalling is not sufﬁcient for speciﬁc
endpoints; alternatively, Tyr317 may itself trigger speciﬁc pathways.
Furthermore, the inhibitory effect of ShcY317F may be due to
competition not only with endogenous Shc, but also with other
adaptors docking the same TRK-T3 site.
The relevance of these studies is the possibility to block the
transforming potential of TRK oncogenes by interfering with
signalling through the Y317 residue of Shc. However, the mechan-
ism responsible for this inhibitory effect, in particular the apoptotic
process, deserves further investigations.
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Table 1 Effect of ShcY317F on TRK-T3 induced transformed phenotype
Early
Crisis, apoptosis
and rescue Late
Selective agent Trans. Eff. Morph.
TRK-T3
expression
ShcY317F
expression + 7 Morph.
TRK
expression
ShcY317F
expression
Hyg 0.5 10/10 I + + 10/10 F 7 +
None 1 10/10 I + + 5/10 F 7 +
5/10 I + 7
Hyg+G418 0.5 10/10 I + + 10/10 I + +
Early: Weeks 0–3 after isolation. Late: Weeks 4–6 after isolation. Transf. Eff.: Transforming efﬁciency. Morph.: Morphology. I: Intermediate. F: Flat. Hyg: Hygromycin. Analysis of
morphology, TRK-T3 and ShcY317F expression on foci isolated from NY317F cells transfected with TRK-T3 and selected in medium without selective agents or containing
hygromycin (25 mgm l
71) or hygromycin plus G418 (400 mgm l
71). Ten foci from each selection type were analysed.
Hygromycin
G418
+
+
–
+
+
–
Hygromycin
G418
+
+
–
+
+
–
–
–
TRK-T3
IP: aTRK
ShcY317F
IP: aHA
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–
Figure 5 Effect of selective agents on the phenotype and TRK-T3 and ShcY317F protein expression on focus 3.9HG. (A) The 3.9HG cell line, generated
by transfection of NY317F cells with TRK-T3, was selected in medium containing both hygromycin (25 mgm l
71) and G418 (400 mgm l
71) and displayed an
‘intermediate’ phenotype. The 3.9HG cells were cultured for four weeks in the absence or in the presence of different combinations of selective agents
(hygromycin+G418, G418, hygromycin). (B) Cell extracts from the 3.9HG cells cultured under the four different conditions were immunoprecipitated
and immunoblotted with anti-TRK and anti-HA antibodies to show the level of TRK-T3 and ShcY317F proteins.
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